Insider Selling: Vir Biotechnology (NASDAQ:VIR) CFO Sells 2,089 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CFO Jason O’byrne sold 2,089 shares of the stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $7.45, for a total transaction of $15,563.05. Following the transaction, the chief financial officer directly owned 164,249 shares of the company’s stock, valued at approximately $1,223,655.05. This trade represents a 1.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Vir Biotechnology Stock Performance

Shares of Vir Biotechnology stock traded up $2.06 on Tuesday, reaching $9.49. The company had a trading volume of 38,240,174 shares, compared to its average volume of 1,972,225. The firm’s 50 day moving average price is $6.80 and its two-hundred day moving average price is $5.99. Vir Biotechnology, Inc. has a 52-week low of $4.16 and a 52-week high of $10.29. The firm has a market cap of $1.32 billion, a PE ratio of -3.00 and a beta of 1.69.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.11. The firm had revenue of $64.07 million during the quarter, compared to the consensus estimate of $19.91 million. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 47.14%. The firm’s revenue for the quarter was up 417.8% on a year-over-year basis. During the same quarter last year, the firm earned ($0.76) EPS. As a group, sell-side analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in VIR. ARCH Venture Management LLC purchased a new stake in Vir Biotechnology during the second quarter worth approximately $65,100,000. Aberdeen Group plc raised its holdings in Vir Biotechnology by 51.6% during the third quarter. Aberdeen Group plc now owns 1,526,265 shares of the company’s stock worth $8,715,000 after purchasing an additional 519,374 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Vir Biotechnology during the second quarter worth approximately $289,000. Ensign Peak Advisors Inc lifted its position in shares of Vir Biotechnology by 812.7% during the 2nd quarter. Ensign Peak Advisors Inc now owns 582,981 shares of the company’s stock worth $2,938,000 after buying an additional 519,107 shares during the last quarter. Finally, Corton Capital Inc. acquired a new position in shares of Vir Biotechnology in the 2nd quarter valued at $114,000. 65.32% of the stock is owned by institutional investors and hedge funds.

Key Vir Biotechnology News

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas strategic collaboration: Vir announced a global co‑development/co‑commercialization collaboration with Astellas for prostate cancer candidate VIR‑5500 that includes $335M upfront/near‑term payments, up to $1.37B in additional milestones, a 50/50 U.S. profit/loss split, Astellas leading U.S. commercialization and ex‑U.S. rights, plus tiered double‑digit ex‑U.S. royalties — a major de‑risking and validation event for the program. Read More.
• Positive Sentiment: Encouraging Phase 1 VIR‑5500 data: Updated trial results show a favorable safety profile and meaningful activity (reported ORR ~45% at higher doses in later cohorts), supporting the value of the asset and underpinning the Astellas deal. Read More.
• Positive Sentiment: Quarterly beat and strong revenue growth: Q4 EPS of ($0.31) beat estimates and revenue of $64.1M significantly exceeded the consensus (~$19.9M), with revenue up ~418% year‑over‑year — evidence of commercial traction and stronger near‑term financial performance. Read More.
• Positive Sentiment: Analyst upgrade: Needham raised its price target to $18 and maintained a buy rating, adding institutional validation and support for higher upside expectations. Read More.
• Neutral Sentiment: Broad media coverage and analyst commentary: Multiple outlets (Forbes, Seeking Alpha, MSN) are highlighting the deal, data and earnings beat — amplifying attention and trading volume but not adding new fundamentals. Read More.
• Neutral Sentiment: Company disclosures and materials: Earnings call transcript and slide deck provide more color on pipeline prioritization (HDV, oncology) and capital deployment plans. Read More.
• Negative Sentiment: Proposed public offering: Vir filed to sell additional shares, which can be dilutive and weigh on near‑term share price despite the cash proceeds. Read More.
• Negative Sentiment: Ongoing losses and wide negative margins: The company reported a large 2025 net loss (and very negative margins), so long‑term value depends on successful development/commercial execution and milestone/cash management. Read More.

Analyst Ratings Changes

Several equities analysts recently issued reports on VIR shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Monday, December 22nd. Raymond James Financial upgraded shares of Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price target on the stock in a research note on Tuesday. Barclays reissued an “overweight” rating and set a $30.00 price target on shares of Vir Biotechnology in a research report on Tuesday. Needham & Company LLC lifted their price objective on shares of Vir Biotechnology from $14.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Vir Biotechnology in a research note on Tuesday, December 30th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Vir Biotechnology currently has a consensus rating of “Moderate Buy” and an average target price of $19.88.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.